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Most pituitary adenomas are benign and exhibit slow 
expansive growth; however, about a third of pituitary 
adenomas are invasive, and some of them exhibit more 
aggressive clinical behaviour [1]. Surgical and radiation 
treatment are the cornerstones of clinical management, 
further medical treatment options are efficient mostly 
for endocrine active tumours. We present a case of a pi-
tuitary adenoma with ACTH-positive immunochem-
istry without clinical or endocrine laboratory markers 
of Cushing´s disease, and our considerations for the 
selection of therapeutic options.
A then 17-year-old male patient had his first pituitary 
operation in 2003, revealing a clinically silent immu-
nohistochemically ACTH-positive pituitary adenoma 
(Fig. 1). He presented in our hospital in 2019 because of 
epileptic seizures for the first time; he had previously 
been living in Styria. Since his diagnosis 4 transsphe-
noidal and transcranial operations had been effectuated 
as well as radiation therapy (2007 and gamma knife in 
2010) and an unsuccessful medical approach with te-
mozolomide. Nonetheless, continuous tumour growth 
had taken place, causing visual restrictions because 
of compression of the chiasma opticum. Remarkably, 
his Ki-67 level had always been < 4%. MRI presented 
a 7.5-cm tumour relapse in April 2019.  
Endocrine evaluation showed central hypothyroidism 
and testosterone deficiency, which were substituted; the 
adrenocortical axis appeared normal as at any time point. 
Constant visual field impairment was present and some 
mood disturbances; otherwise, the patient was in good 
clinical conditions. The medical record included a history 
of polytoxic drug abuse. In search of a possible medical 
approach, we discussed the therapies used in Cushing’s 
disease targeting the pituitary [2]. PET imaging was done 
with 18F-Fallypride, which is specific for dopamine recep-
tor type 2 [3, 4]. The tumour showed marked uptake of 
the tracer (Fig. 2), and we indicated therapy with caber-
goline at 2 mg/week. We also measured SSTR immuno-
histochemistry on preserved tumour material which was 
negative for subtype 2 and 5 (Fig. 3 and 4), so a possible 
target for pasireotide was not present. Otherwise, PD-L1 
was positive in 70% of all tumour cells. Therefore, specific 
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Figure 1. More than 10% of the tumour cells stained positive 
for ACTH, magnification 20×
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sion of SSTR subtype 2 or 5 the tumour board decided 
against a trial with pasireotide. Conservative therapy 
with dopamine agonists is effective in cases of clinically 
non-functioning pituitary adenomas, depending on the 
expression of D2 receptors [6]. This condition could be 
proven via D2 receptor PET/CT, and therefore a specific 
endocrine therapy was initiated. The decision for ad-
ditional antibody therapy with nivolumab was based 
on the pathohistological findings. A role for immunohis-
tochemistry in the evaluation of tumour specimen and 
receptor-based nuclear medicine imaging was present 
here for decision-making in personalized medicine.
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antibody therapy with nivolumab was started in June 
2019. He received in total 9 cycles of nivolumab until 
reaching the limiting dose. Stable disease was observed 
by MRI in November 2019. Then the patient refused any 
further tumour-specific therapy; clinical worsening in-
cluding diminishing vision and reappearance of seizures 
took place. MRI control in May 2020 showed a marked 
tumour progress, and so palliative care was organized.  
Silent corticotrope adenomas are rare entities, gi-
ant adenomas, in particular, seldom occur. Aggressive 
behaviour would have been expected to be related to 
a high Ki-67 index, which was not the case here. This 
circumstance may also partially explain the disappoint-
ing results of radiation therapy. 
The search for medical therapeutic options in this 
case is problematic because any medication in this thera-
peutically refractory constellation of a clinically silent 
ACTH-positive pituitary adenoma has to be considered 
experimental. Corticotrope adenomas with invasive 
growth have been shown to lose SSTR5 and D2 receptor 
expression [5]. Because there was no significant expres-
Figure 4. The weak, fine granular, mostly nuclear SSTR5-positivity 
is non-specific, the cell membranes appear SSTR5-negative, 
magnification 40×
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Figure 2a. 18F-Fallypride PET presented high D2-receptor 
targeting uptake of the tumour with a SUVmax = 13, comparable 
to the physiological high retention of the putamen; B. PET images 
were also fused to MRI
Figure 3. The tumour cells are SSTR2-negative, magnification 40×
